SUVRETTA CAPITAL MANAGEMENT LLC 13D and 13G filings for Mereo BioPharma Group plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:18 pm Sale | 2024-09-30 | 13G | Mereo BioPharma Group plc MREO | SUVRETTA CAPITAL MANAGEMENT LLC | 0 0.000% | -36,854,190 (Position Closed) | Filing |
| 2024-02-13 5:26 pm Purchase | 2023-12-31 | 13G | Mereo BioPharma Group plc MREO | SUVRETTA CAPITAL MANAGEMENT LLC | 36,854,190 5.300% | 32,000 (+0.09%) | Filing |
| 2023-02-13 1:21 pm Sale | 2022-12-31 | 13G | Mereo BioPharma Group plc MREO | SUVRETTA CAPITAL MANAGEMENT LLC | 36,822,190 5.900% | -8,888,145 (-19.44%) | Filing |
| 2022-02-11 4:37 pm Purchase | 2021-12-31 | 13G | Mereo BioPharma Group plc MREO | SUVRETTA CAPITAL MANAGEMENT LLC | 45,710,335 8.400% | 13,882,835 (+43.62%) | Filing |
| 2021-02-19 4:27 pm Purchase | 2021-02-10 | 13G | Mereo BioPharma Group plc MREO | SUVRETTA CAPITAL MANAGEMENT LLC | 31,827,500 5.900% | 31,827,500 (New Position) | Filing |